Aclidinium bromide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Aclidinium bromide" in English language version.

refsWebsite

Global rank English rank

399^th place

333^rd place

4^th place

4^th place

2^nd place

2^nd place

3,984^th place

2,622^nd place

68^th place

117^th place

low place

low place

1semanticscholar.org

11^th place

8^th place

102^nd place

76^th place

low place

low place

doi.org

Gavaldà A, Miralpeix M, Ramos I, et al. (2009). "Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile". J Pharmacol Exp Ther. 331 (2): 740–51. doi:10.1124/jpet.109.151639. PMID 19710368. S2CID 10533142.
Ni H, Soe Z, Moe S (September 2014). "Aclidinium bromide for stable chronic obstructive pulmonary disease". The Cochrane Database of Systematic Reviews. 2014 (9): CD010509. doi:10.1002/14651858.CD010509.pub2. PMC 8922974. PMID 25234126.

drugs.com

FDA Professional Drug Information on Tudorza Pressair.
"Brimica Genuair: Uses, Side Effects, Benefits/Risks". Drugs.com. 19 November 2014. Retrieved 26 July 2020.
"Duaklir Genuair: Uses, Side Effects, Benefits/Risks". Drugs.com. 19 November 2014. Retrieved 26 July 2020.

europa.eu

ema.europa.eu

"Bretaris Genuair EPAR". European Medicines Agency. 20 July 2012. Retrieved 21 June 2024.

frx.com

news.frx.com

"Forest Laboratories and Almirall Announce FDA Approval of Tudorza Pressair for the Long-Term Maintenance Treatment of COPD" (Press release). Forest Laboratories. Retrieved 24 July 2012.

handle.net

hdl.handle.net

World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

menarini.com

"Almirall and Menarini sign a licence agreement and commercial alliance for Aclidinium in the majority of European member states and a number of non-EU countries" (Press release). Menarini. Retrieved 26 March 2012.

nih.gov

pubmed.ncbi.nlm.nih.gov

Gavaldà A, Miralpeix M, Ramos I, et al. (2009). "Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile". J Pharmacol Exp Ther. 331 (2): 740–51. doi:10.1124/jpet.109.151639. PMID 19710368. S2CID 10533142.
Ni H, Soe Z, Moe S (September 2014). "Aclidinium bromide for stable chronic obstructive pulmonary disease". The Cochrane Database of Systematic Reviews. 2014 (9): CD010509. doi:10.1002/14651858.CD010509.pub2. PMC 8922974. PMID 25234126.

ncbi.nlm.nih.gov

Ni H, Soe Z, Moe S (September 2014). "Aclidinium bromide for stable chronic obstructive pulmonary disease". The Cochrane Database of Systematic Reviews. 2014 (9): CD010509. doi:10.1002/14651858.CD010509.pub2. PMC 8922974. PMID 25234126.

semanticscholar.org

api.semanticscholar.org

Gavaldà A, Miralpeix M, Ramos I, et al. (2009). "Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile". J Pharmacol Exp Ther. 331 (2): 740–51. doi:10.1124/jpet.109.151639. PMID 19710368. S2CID 10533142.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.